TW202104269A - 抗ｃｄ３８抗體和調配物 - Google Patents

抗ｃｄ３８抗體和調配物 Download PDF

Info

Publication number
TW202104269A
TW202104269A TW109113639A TW109113639A TW202104269A TW 202104269 A TW202104269 A TW 202104269A TW 109113639 A TW109113639 A TW 109113639A TW 109113639 A TW109113639 A TW 109113639A TW 202104269 A TW202104269 A TW 202104269A
Authority
TW
Taiwan
Prior art keywords
amino acid
antibody
seq
acid sequence
heavy chain
Prior art date
Application number
TW109113639A
Other languages
English (en)
Chinese (zh)
Inventor
貝堤翠西 卡梅隆
馬里耶勒 凱隆布隆戴爾
傑奎斯 仲馬
艾倫 富尼耶
喬納森 金斯伯里
辛德琳 萊蒙
布萊恩 莫瑞
奈森 奧斯博格
薩凱 帕特克
奧多 安琪拉 瓦伊倫
張子川
Original Assignee
法商賽諾菲公司
美商健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司, 美商健臻公司 filed Critical 法商賽諾菲公司
Publication of TW202104269A publication Critical patent/TW202104269A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW109113639A 2019-04-23 2020-04-23 抗ｃｄ３８抗體和調配物 TW202104269A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
US201962859699P 2019-06-10 2019-06-10
US62/859,699 2019-06-10
EP20305146 2020-02-17
EP20305146.1 2020-02-17
EP20305145 2020-02-17
EP20305145.3 2020-02-17

Publications (1)

Publication Number Publication Date
TW202104269A true TW202104269A (zh) 2021-02-01

Family

ID=70739160

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109113639A TW202104269A (zh) 2019-04-23 2020-04-23 抗ｃｄ３８抗體和調配物

Country Status (14)

Country Link
EP (1) EP3958898A1 (fr)
JP (1) JP2022529502A (fr)
KR (1) KR20220003562A (fr)
CN (1) CN114269375A (fr)
AU (1) AU2020261039A1 (fr)
BR (1) BR112021021060A2 (fr)
CA (1) CA3137365A1 (fr)
CO (1) CO2021015462A2 (fr)
IL (1) IL287477A (fr)
MA (1) MA55761A (fr)
MX (1) MX2021012967A (fr)
SG (1) SG11202111602YA (fr)
TW (1) TW202104269A (fr)
WO (1) WO2020219681A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023843A1 (fr) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited Formulation pharmaceutique d'un anticorps thérapeutique et ses préparations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE443084T1 (de) 2004-07-10 2009-10-15 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer

Also Published As

Publication number Publication date
JP2022529502A (ja) 2022-06-22
SG11202111602YA (en) 2021-11-29
CN114269375A (zh) 2022-04-01
KR20220003562A (ko) 2022-01-10
AU2020261039A1 (en) 2021-12-09
CO2021015462A2 (es) 2021-12-10
MX2021012967A (es) 2022-01-18
MA55761A (fr) 2022-03-02
EP3958898A1 (fr) 2022-03-02
BR112021021060A2 (pt) 2021-12-14
IL287477A (en) 2021-12-01
CA3137365A1 (fr) 2020-10-29
WO2020219681A1 (fr) 2020-10-29

Similar Documents

Publication Publication Date Title
US11820818B2 (en) Multi-chain polypeptide-containing tri-specific binding molecules
US10493140B2 (en) Anti-ICOS agonist antibodies and uses thereof
US20230416395A1 (en) Anti-cd38 antibodies and formulations
KR20220122628A (ko) 항-ccr8 항체 및 이의 용도
US10501552B2 (en) Multivalent molecules comprising DR5-binding domains
KR20150058236A (ko) 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
KR20230119259A (ko) 항-인간 vista 항체 및 이의 용도
JP2023528036A (ja) Ｔｉｇｉｔに対する抗体
KR20240035758A (ko) 조작된 폴리펩타이드
CN111108127A (zh) 用于治疗神经变性和炎性疾病的特异性结合cd38的化合物
US11926667B2 (en) Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
KR20130100918A (ko) Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능
TW202104269A (zh) 抗ｃｄ３８抗體和調配物
JP7368007B2 (ja) 免疫関連疾患の予防または治療用組成物
CA3227227A1 (fr) Anticorps multispecifiques se liant a cd20, nkp46, cd16 et conjugues a il-2
US20240182559A1 (en) MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
RU2808632C2 (ru) Виды комбинированной терапии рака, нацеливающиеся на cd38 и tgf-бета
JP2022542863A (ja) 抗ｍＧｌｕＲ５抗体及びその使用